汇宇制药：旗下依托泊苷注射液、氟尿嘧啶注射液获得美国FDA批准

Core Viewpoint - Recently, Huiyu Pharmaceutical announced that it has received notification from the U.S. Food and Drug Administration (FDA) that its New Drug Applications (NDA) for Etoposide Injection and Fluorouracil Injection have been approved, allowing the company to produce and sell these products in the U.S. market through overseas partners [1] Group 1 - The FDA approval will help the company expand its sales in the U.S. market, strengthen its product supply chain, and enrich its product portfolio [1] - The approval lays a foundation for the sustainable development of the company's international market [1] - Although the company has begun preparations for the initial sales launch, there is significant uncertainty regarding future revenue due to the non-uniqueness of the products and competition from similar products [1]